Latest News and Press Releases

SHANGHAI, China and NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of...

Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executivesLicensed...

SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

与诺华公司的合作内容包括以 4,000 万美元收购 CBMG 的1,458,257 股股票，对其开展股权投资，股票价格为每股 27.43 美元CBMG 将授权诺华公司在全球范围内使用其特定专有技术CBMG 将在中国生产和供应 Kymriah® (tisagenlecleucel） 上海和加利福尼亚州库比蒂诺, Sept. 27, 2018 (GLOBE NEWSWIRE) --...

SHANGHAI, China and CUPERTINO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- China Food and Drug Administration (CFDA) Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19...

SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...